Astec LifeSciences Second Quarter 2025 Earnings: Misses Expectations

Astec LifeSciences (NSE:ASTEC) Second Quarter 2025 Results

Key Financial Results

• Revenue: ₹1.01b (down 9.2% from 2Q 2024).
• Net loss: ₹385.6m (loss widened by 187% from 2Q 2024).
• ₹19.66 loss per share (further deteriorated from ₹6.85 loss in 2Q 2024).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Astec LifeSciences Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 16%. Earnings per share (EPS) also missed analyst estimates by 22%.

Looking ahead, revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India.

Performance of the Indian Chemicals industry.

The company's shares are down 2.0% from a week ago.

Risk Analysis

Before you take the next step you should know about the 1 warning sign for Astec LifeSciences that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.